Discussion {#onco12184-sec-0001}
==========

The unproven hypothesis that angiogenesis is a key step in the development and metastasis of solid tumors \[[1](#onco12184-bib-0001){ref-type="ref"}\], especially mRCC \[[2](#onco12184-bib-0002){ref-type="ref"}\], led to the development of a large number of agents whose putative target was the vascular endothelial growth factor (VEGF) pathway. Several of these agent were shown to have modest activity in the therapy of mRCC and this led to their approval by regulatory agencies. However, given their limited activity, their use in combinations has been extensively explored. We studied the combination of ixabepilone, a microtubule‐targeting epothilone \[[3](#onco12184-bib-0003){ref-type="ref"}\], \[[4](#onco12184-bib-0004){ref-type="ref"}\], with bevacizumab, a monoclonal antibody that binds VEGF.

Preclinical data from several in vivo models including breast, kidney, lung, and colon cancers demonstrated increased activity of ixabepilone in combination with bevacizumab, suggesting a synergistic effect in both antitumor and antiangiogenic activities and the absence of overlapping toxicities \[[5](#onco12184-bib-0005){ref-type="ref"}\]. More recently, randomized trials reported acceptable activities and toxicities of combined therapy in platinum/taxane‐resistant cervical‐uterine \[[6](#onco12184-bib-0006){ref-type="ref"}\] and locally recurrent or metastatic breast cancer \[[7](#onco12184-bib-0007){ref-type="ref"}\]. Best percentage change from baseline for target lesions per patient.image

This investigation was designed as a single‐arm phase II multi‐center trial with a primary aim of determining the objective response rate of ixabepilone plus bevacizumab using RECIST criteria in patients with relapsed or refractory mRCC. We also evaluated PFS, OS, and toxicities of the combined therapy. The observed activity of the combined therapy was less than originally expected, considering results in an earlier phase II study of ixabepilone in renal cancer that demonstrated an objective response rate of 13% \[[16](#onco12184-bib-0008){ref-type="ref"}\]. Regarding side effects, the tested combination was well tolerated without major side effects or deaths related to treatment. image

Despite the low response rate of 11.3%, the median PFS of 8.3 month and OS of 15 months compare favorably with putative antiangiogenic agents approved for mRCC in second‐line treatment before 2015 \[[8](#onco12184-bib-0009){ref-type="ref"}\], \[[9](#onco12184-bib-0010){ref-type="ref"}\], \[[10](#onco12184-bib-0011){ref-type="ref"}\]. Furthermore, with a median number of two previous lines of treatment, a majority of patients were receiving this treatment in third line, making this combination potentially active in the third‐line setting. However, recent advances in immunotherapy for RCC restrict the potential scope of this combination.

Trial Information {#onco12184-sec-1101}
=================

DiseaseRenal cell carcinoma -- clear cellStage of Disease/TreatmentMetastatic/AdvancedPrior Therapy1 prior regimenType of Study -- 1Phase IIType of Study -- 2Single armPrimary EndpointOverall response rateSecondary EndpointOverall survivalSecondary EndpointProgression‐free survivalSecondary EndpointToxicityInvestigator\'s AnalysisActive but results overtaken by other developments

Drug Information for Phase II Ixabepilone + Bevacizumab {#onco12184-sec-1201}
=======================================================

Drug 1 Generic/Working nameIxabepiloneTrade nameIxempraCompany nameBristol‐Myers SquibbDrug typeMicrotubule inhibitorDrug classMicrotubule‐targeting agentDose6 milligrams (mg) per squared meter (m^2^)RouteIVDrug 2 Generic/Working nameBevacizumabTrade nameAvastinCompany nameGenentech/RocheDrug typeAntibodyDrug classAngiogenesis ‐ VEGFDose15 milligrams (mg) per kilogram (kg)RouteIV

Patient Characteristics for Phase II Ixabepilone + Bevacizumab {#onco12184-sec-1301}
==============================================================

Number of patients, male23Number of patients, female7StageMetastatic or recurrentAgeMedian (range): 62.3 (44.3--78.8)Number of prior systemic therapiesMedian (range): 2 (1--5)Performance Status: ECOG0 --- 21 --- 242 --- 43 ---unknown ---Cancer Types or Histologic SubtypesClear cell, 30

Primary Assessment Method for Phase II Ixabepilone + Bevacizumab {#onco12184-sec-1401}
================================================================

Assessment Number of patients screened40Number of patients enrolled30Number of patients evaluable for toxicity30Number of patients evaluated for efficacy30Evaluation methodRECIST 1.1Response assessment CR*n* = 0 (0%)Response assessment PR*n* = 3 (10%)Response assessment SD*n* = 19 (63.3%)Response assessment PD*n* = 8 (26.7%)Response assessment OTHER*n* = 0 (0%)(Median) duration assessments PFS8.3 months, CI: 4.9--10.6(Median) duration assessments OS15.0 months, CI: 11.3--29.8Kaplan‐Meier Time unitsMonths

 {#onco12184-sec-7441}

Best percentage change from baseline for target lesions per patient.image

Secondary Assessment Method for Phase II Ixabepilone + Bevacizumab (PFS) {#onco12184-sec-1402}
========================================================================

Assessment Number of patients evaluated for efficacy30Kaplan‐Meier Time unitsmonths

 {#onco12184-sec-1501}

imageJohn Wiley & Sons, Ltd.

 {#onco12184-sec-7641}
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Secondary Assessment Method for Phase II Ixabepilone + Bevacizumab (OS) {#onco12184-sec-1002}
=======================================================================

Assessment Number of patients evaluated for efficacy30Kaplan‐Meier Time unitsmonths

 {#onco12184-sec-1723}

imageJohn Wiley & Sons, Ltd.
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image

Adverse Events: Phase II Ixabepilone + Bevacizumab {#onco12184-sec-1801}
==================================================

imageJohn Wiley & Sons, Ltd.[^2]

Assessment, Analysis, and Discussion {#onco12184-sec-2201}
====================================

CompletionStudy completedInvestigator\'s AssessmentActive but results overtaken by other developments

 {#onco12184-sec-2271}

Renal cell carcinoma is among the ten most frequently diagnosed cancers in the general population in the U.S. \[[2](#onco12184-bib-0002){ref-type="ref"}\], with approximately 63,000 new cases and almost 14,000 deaths from RCC each year \[[12](#onco12184-bib-0012){ref-type="ref"}\]. Given its refractory nature, mRCC remains a difficult problem with 5‐year survival rates of 8% \[[2](#onco12184-bib-0002){ref-type="ref"}\].

Interest in the angiogenesis hypothesis, especially its putative role in RCC led to the development of innumerable "antiangiogenic agents" that sought to interdict signaling through the VEGF pathway. Despite the approval of several similar agents for the treatment of mRCC by regulatory agencies, efficacy was modest and short‐lived, in part due to the emergence of resistance \[[13](#onco12184-bib-0013){ref-type="ref"}\]. This has provided the impetus to develop combination regimens using antiangiogenic agents in the hopes of improving therapeutic efficacy. For example, although initial studies with single‐agent bevacizumab in patients with mRCC demonstrated a significant increase in time to progression \[[14](#onco12184-bib-0014){ref-type="ref"}\], its efficacy was not consider sufficient for use as a single agent. It was then explored and subsequently approved by regulatory agencies for the treatment of mRCC in combination with interferon alfa, based on the results of a phase III trial \[[15](#onco12184-bib-0015){ref-type="ref"}\]. With this background, we embarked on a clinical trial exploring the activity of the combination of bevacizumab with ixabepilone. In preclinical studies, ixabepilone, a non‐taxane microtubule‐stabilizing agent, had been shown to be active against cancer cell lines intrinsically insensitive to taxanes as well as cell lines that had developed resistance. To date, the only regulatory approval for ixabepilone is in metastatic breast cancer as a monotherapy or in combination with capecitabine based on an open‐label phase III trial that enrolled 752 patients \[[16](#onco12184-bib-0008){ref-type="ref"}\].

In mRCC, we initially explored the activity of ixabepilone monotherapy in previously untreated patients \[[16](#onco12184-bib-0008){ref-type="ref"}\] using the same schedule of administration---6 mg/m^2^/day, for 5 consecutive days every 3 weeks---used in combination with bevacizumab in this trial. In the previous trial, the overall response rate was 13% with a median duration of response of 5.5 months and an OS of 19.25 months \[[16](#onco12184-bib-0008){ref-type="ref"}\]. This regimen is different from that approved in breast cancer (40 mg/m^2^ every 3 weeks) and was chosen because of the lower rate of neurotoxicity. Another phase II trial with the 40 mg/m^2^ every 3 weeks was published with 12 patients and no objective responses \[[17](#onco12184-bib-0017){ref-type="ref"}\]. Given that both ixabepilone and bevacizumab had demonstrated modest activity in mRCC, appeared not to have overlapping toxicities, and had shown encouraging activity in preclinical models, we chose to explore the combination of ixabepilone plus bevacizumab in mRCC. The results demonstrated the combination was well tolerated with modest activity.

In our view, the recent approval of cabozantinib \[[18](#onco12184-bib-0018){ref-type="ref"}\] and especially nivolumab \[[19](#onco12184-bib-0019){ref-type="ref"}\] for the therapy of mRCC in second line \[[2](#onco12184-bib-0002){ref-type="ref"}\] make the further development of the tested combination very difficult. Accrual for this trial that began in 2009 was challenging and would be even more challenging in 2017.

[ClinicalTrials.gov Identifier](http://ClinicalTrials.gov): [NCT00923130](https://clinicaltrials.gov/ct2/show/NCT00923139)
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[Click here to access other published clinical trials](http://theoncologist.alphamedpress.org/cgi/collection/clinical-trial-results).
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